The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...

As the potential of GLP-1 agonists for addiction gains traction, big pharma is also starting to take notice, namely the two ...

We recently published an article titled Jim Cramer Discusses These 11 Stocks & President Trump’s Tariffs. In this article, we ...

Depression risk for patients receiving GLP-1 RA was slightly higher than those receiving SGLT-2i and lower than those receiving DPP-4i.

It’s hard to turn on the TV these days without seeing ads for drugs like Ozempic, Wegovy, Zepbound or Mounjaro. These ...

Eating Patterns in America” report highlighted the growing year-over-year trend toward at-home dining, with 86% of eating ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

For kidney transplant recipients with type 2 diabetes, use of glucagon-like peptide-1 receptor agonists was associated with ...

Novo Nordisk faces formidable challenges from Eli Lilly and new rivals, but its first-mover advantage and expanded ...

ANAHEIM, CALIF. — Evolving consumer need states combined with unpredictable economic factors are changing the way snack manufacturers interact with customers today, according to a panel of snack ...

Patients who continued Ozempic through total joint arthroplasty had higher risk for complications compared with those who stopped GLP-1RAs before surgery.

Altimmune said on Thursday that it plans to test its lead experimental obesity drug, pemvidutide, to potentially treat alcohol use disorder and alcohol-associated liver disease. WHY IT'S IMPORTANT ...